Cipla Ltd


BSE: 500087 | NSE: CIPLA | ISIN: INE059A01026 
Market Cap: [Rs.Cr.] 33,489 | Face Value: [Rs.] 2
Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

 Discuss this stock

Board Meet

29-May-13 
Cipla Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on May 29, 2013, inter alia, to consider the Annual Audited Accounts for the year ended March 31, 2013 and Recommendation of Dividend, if any. 
27-Feb-13 
With reference to the earlier announcement dated November 21, 2012, whereby, company had informed the exchanges that the Company is in preliminary discussions to acquire a 51% equity shareholding in Medpro. Cipla Ltd has now informed BSE that the Board of Directors of the Company at its meeting held February 27, 2013,have decided to make and have made a firm offer to the Board of Directors of Medpro to acquire (either through itself or through its nominated subsidiary) 100% of the ordinary shares of Medpro at a price of ZAR 10.00 per share, and to settle all outstanding share options therein. Based on Medpro's current shares and share options outstanding, the total consideration payable by the Company or its nominated subsidiary would be approximately $512 million. The Board of Directors of Medpro have recommended to its shareholders to vote in favour of the offer. Also, the independent expert appointed by the Independent board of Medpro is of the opinion the offer is fair and reasonable to the Medpro shareholders. 
06-Feb-13 
Cipla Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on February 06, 2013, inter alia, to consider Unaudited Financial Results for third quarter ended December 31, 2012 (Q3). Cipla Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 06, 2013, inter alia, has decided to issue 10,00,000 stock options to Mr. Subhanu Saxena, Chief Executive Officer subject to requisite approvals. The options would be granted to Mr. Subhanu Saxena by the Compensation Committee on mutually acceptable terms. The Company is seeking approval of shareholders to the aforesaid proposal by means of postal ballot and has appointed Mr. B. Narasimhan, Practising Company Secretary as Scrutinizer for conducting the postal ballot process. (As per BSE Announcement Dated on 07.02.2013) 
05-Nov-12 
Cipla Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on November 05, 2012, inter alia, to consider Unaudited Financial Results for second quarter ended September 30, 2012 (Q2). 
31-Jul-12 
Cipla Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on July 31, 2012, inter alia, to consider Unaudited Financial Results for first quarter ended June 30, 2012 (Q1). 

AGM

17-Aug-12
Cipla Ltd has informed BSE that the 76th Annual General Meeting (AGM) of the Company will be held on August 17, 2012. Cipla Ltd has informed BSE regarding the details of the Voting Results at the 76th Annual General Meeting of the Company held on August 17, 2012 under Clause 35A. (As Per BSE Announcement Dated on 20.08.2012) Cipla Ltd has informed BSE that the 76th Annual General Meeting (AGM) of the Company was held on August 17, 2012. (As Per BSE Announcement Dated on 21.08.2012) 
25-Aug-11
AGM 25.08.2011 Cipla Ltd has informed BSE that the members at the 75th Annual General Meeting (AGM) of the Company held on August 25, 2011, inter alia, have passed the following resolutions: 1. Balance Sheet as at March 31, 2011, the Profit and Loss Account for the year ended on that date together with the schedules annexed thereto as well as the reports of the Board of Directors and Auditors thereon were adopted. 2. Interim Dividend paid at the rate of 40% on 80,29,21,357 Equity Shares of Rs. 2/- each for the financial year ended March 31, 2011 was confirmed. Final Dividend at the rate of 100% on 80,29,21,357 Equity Shares of Rs 21- each for the financial year ended March 31, 2011 was declared. 3. Mr. M. R. Raghavan has been re-appointed as Director of the Company. 4. Mr. Pankaj Patel has been re-appointed as Director of the Company. 5. M/s. V. Sankar Aiyar & Co., Chartered Accountants together with M/s. R. G. N. Price & Co., Chartered Accountants have been re-appointed as Joint Statutory Auditors of the Company. 6. Appointment of Mr. S. Radhakrishnan as Director of the Company and ratification of his appointment as Whole-time Director with effect from November 12, 2010 was approved. 7. Appointment of Mrs. Samina Vaziralli as a member of management team of the Company was approved. 
25-Aug-10
Cipla Limited has informed the Exchange that the Annual General Meeting of the Company will be held on August 25, 2010. Cipla Ltd has informed BSE that at the 74th Annual General Meeting of the Members of the Company held on August 25, 2010, all resolutions as mentioned in the Notice were passed with requisite majority. A brief summary of the resolutions passed at the Annual General Meeting are as under: 1. Balance Sheet as at March 31, 2010, the Profit and Loss Account for the year ended on that date together with the schedules annexed thereto as well as the reports of the Board of Directors and Auditors thereon were adopted. 2. Dividend at the rate of 100% on 80,29,21,357 Equity Shares of Rs. 2/- each for the financial year ended March 31, 2010 was declared. 3. Dr. H. R. Manchanda has been re-appointed as Director of the Company 4. Mr. Ramesh Shroff has been re-appointed as Director of the Company. 5. M/s. R.G.N. Price & Co., Chartered Accountants together with M/s. V. Sankar Aiyar & Co., Chartered Accountants have been re-appointed as Joint Statutory Auditors of the Company. 6. Special Resolution for appointment of Mr. Kamil Hamied as a member of Management team of the Company was approved. (As Per BSE Announcement Dated on 27.08.2010) 
26-Aug-09
Cipla Ltd. has informed the Exchange that the Annual General Meeting of the members of the Company will be held on August 26, 2009. Cipla Ltd has informed BSE that the members at the Annual General Meeting (AGM) of the Company held on August 26, 2009, inter alia, have accorded to the following: 1. Adoption of the Balance Sheet of the Company as at March 31, 2009, the Profit and Loss Account for the year ended on that date together with schedules annexed thereto as well as the reports of the Board of Directors and Auditors. 2. Declaration of Dividend at the rate of 100% on 77,72,91,357 Equity Shares of Rs. 2/- each, absorbing an amount of Rs. 155,45,82,714/- for the financial year ended on March 31, 2009. 3. Re-appointment of Mr. S. A. A. Pinto & Mr. V. C. Kotwal as Directors of the Company. 4. Appointment of M/s. R. G. N. Price & Co., Chartered Accountants, Mumbai (the retiring Auditors) together with M/s. V. Sankar Aiyar & Co., Chartered Accountants, Mumbai, appointed as Joint Statutory Auditors of the Company to hold office from the conclusion of this Annual General Meeting until the conclusion of the next Annual General Meeting of the Company, on remuneration, terms & conditions. 5. Authority to the Board to create, offer, issue and allot, in one or more tranches, in domestic and/or international markets, equity shares or warrants simultaneously with non-convertible debentures or foreign currency convertible bonds ('FCCBs') convertible into equity shares of the Company or American Depository Receipts or Global Depository Receipts represented by underlying equity shares of the Company or other securities exchangeable or convertible into equity shares of the Company ('Securities'), for an amount upto Rs. 1500 crore (Rupees One Thousand Five Hundred Crore only), inclusive of such premium, as may be finalised by the Board, at such price being not less than the price determined in accordance with the applicable Guidelines / Regulations issued by SEBI or the Ministry of Finance or the RBI and such issue and allotment to be made on such terms and conditions as may be decided by the Board at the time of issue or allotment of the Securities. (As Per BSE Announcement Website dated on 28.08.2009) 
28-Aug-08
Cipla Ltd. has informed the Exchange that the Annual General Meeting of the Company will be held on August 28, 2008. Cipla Ltd has informed BSE that that the members at the Annual General Meeting (AGM) of the Company held on August 28, 2008, inter alia, have passed the following resolutions: 1. Adoption the Balance Sheet of the Company as at March 31, 2008, the Profit and Loss Account for the year ended on that date together with schedules annexed thereto. 2. Declaration of Dividend at the rate of 100% on Equity Shares of Rs 2/- each for the year ended March 31, 2008. 3. Re-appointment of Dr. M R Raghavan as a Director of the Company. 4. Re-appointment of M/s. R S Bharucha & Co., Chartered Accountants together with M/s. R G N Price & Co., Chartered Accountants as Auditors of the Company to hold office from the conclusion of this Annual General Meeting until the conclusion of the next Annual General Meeting of the Company on remuneration, terms & conditions. 5. Appointment of Mr. Pankaj Patel as a Director of the Company, liable to retire by rotation. 6. Re-appointment of Dr. Y K Hamied as Managing Director of the Company for a further period of five years commencing on August 01, 2008 and ending July 31, 2013, on remuneration, terms & conditions. 7. Re-appointment of Dr. M K Hamied as Joint Managing Director of the Company for a further period of five years commencing on August 01, 2008 and ending July 31, 2013, on remuneration, terms & conditions. (As Per BSE Announcement Website Dated on 29.08.2008) 

EGM

21-Mar-06
Cipla Ltd. has submitted to the Exchange a copy of the Minutes of the deemed EGM of the Company held on March 21, 2006.  
21-Apr-04
EGM 21/04/2004 To approve the sub-division in the face value of equity shares of the company from Rs 10/- to Rs 2/-. Cipla Ltd. has informed the Exchange that an EGM of the Company will be held on April 21,2004 to transact the following business; (1) To obtain consent of the shareholders for the issue and allotment in the aggregate of Rs. 1700 [One thousand Seven Hundred only] equity shares of Rs. 10/- each in the Company credited as fully paid to the equity Shareholders of Oncocare India Private Limited, Medule Pharma Private Limited, Medex Specialities Private Limited, Lancet Pharma Private Limited, Inhaled Technologies Private Limited and Nebumed Pharma Private Limited [whether such members are members of the Company or not] pursuant to and subject to the terms and conditions of the Scheme of Arrangement between Oncocare India Private Limited, Medule Pharma Private Limited, Medex Specialities Private Limited, Lancet Pharma Private Limited, Inhaled Technologies Private Limited and Nebumed Pharma Private Limited and the company and its respective members, provided that the aforesaid allotment shall be subject to the Scheme of Arrangement being approved by the High Court. Further, in the event of the above resolution being carried through with requisite majority, 8500 equity shares of the face value of Rs. 2/- each be issued to the persons as aforesaid instead of 1700 equity shares of Rs. 10/- each. (2) To reduce the nominal value of equity shares of the Company by sub-dividing the equity shares to make it more affordable to the retailinvestor. This will enable the small investors to enter the market. Therefore, it is proposed that the nominal value of equity shares of the Company be reduced from Rs.10/- each to Rs. 2/- each. (3) Consequent to the sub-division of shares, it is necessary to alter the capital clause of the Memorandum and Articles of Association. (As perNSE Bulletin dated on 31/03/2004) The Company has informed that at the Extra Ordinary General Meeting of the members of the Company held on April 21,2004, all the resolutions including resolution for sub-division in facevalue of Equity Shares from Rs 10/-to Rs 2/- were passed with requisite majority. (As per BSE Bulletin dated on 23/04/2004) 

Peer Comparison

Company Market Cap
(Rs. in Cr.)
P/E (TTM)
(x)
P/BV (TTM)
(x)
EV/EBIDTA
(x)
ROE
(%)
ROCE
(%)
D/E
(x)
Sun Pharma.Inds. 100,831.19 70.05 12.43 27.45 26.1 27.0 0.01
Dr Reddy's Labs 34,293.45 27.10 4.50 18.79 14.3 16.6 0.25
Cipla 33,488.96 21.87 4.44 14.11 15.9 19.8 0.03
Ranbaxy Labs. 18,461.97 0.00 9.61 72.87 0.0 0.0 2.38
Wockhardt 18,451.08 109.91 153.35 12.82 237.0 30.3 2.09
Cadila Health. 16,135.56 39.11 6.33 18.45 28.4 24.2 0.40
Glenmark Pharma. 15,542.89 40.26 6.16 23.94 12.7 11.7 0.39
Piramal Enterp. 9,821.55 0.00 0.93 23.66 0.8 2.1 0.07
Ipca Labs. 7,445.80 22.39 5.90 10.09 24.2 23.7 0.49
Torrent Pharma. 6,124.37 11.45 4.69 11.66 29.6 25.5 0.48
Biocon 5,645.00 19.68 2.56 12.20 12.6 13.6 0.08
Aurobindo Pharma 5,264.90 12.52 2.11 22.89 10.7 8.8 1.01
Strides Arcolab 5,195.22 35.42 3.79 46.94 7.3 8.9 0.56
Mylan Lab. 3,273.19 6.80 1.77 0.00 26.9 26.1 0.59
Alembic Pharma 2,406.20 15.29 5.23 5.60 39.5 27.7 1.07

Futures & Options Quote

 
Expiry Date
418.30 0.10  [0.0]%
Instrument: FUTSTK
Expiry Date: 30 May 2013
Open Price: 418.00
Average Price: 418.64
No. of Contracts Traded: 1,713,000
Open Interest: 6,725,000
Underlying: CIPLA
Market Lot: 1000
Previous Close: 418.30
Day’s High | Low: 421.50 | 416.00
Turnover (Cr.): 71.71
Open Int. Change: -142,000.00 ( [2.1]% )
View detailed F& O quotes >>

Key Information

Key Executives:

Y K Hamied , Chairman (Non-Executive)  

M K Hamied , Joint Managing Director  

S Radhakrishnan , Whole-time Director  

V C Kotwal , Director  


Company Head Office / Quarters:
Mumbai Central,
,
Mumbai,
Maharashtra-400008
Phone : 91-22-23025272/23095521/23082891
Fax : 91-22-23008101/23070013/23070393
E-mail : cosecretary@cipla.com
Web : http://www.cipla.com
Registrars:
Karvy Computershare Pvt Ltd
Plot No 17-24
Vittal Rao Nagar
Madhapur
Hyderabad-500081

Fund Holding

 
Scheme Name No. of Shares
HDFC Equity Fund - (G) 4,368,000
HDFC Top 200 Fund (G) 2,804,699
HDFC Tax Saver Fund (G) 2,008,045

Calendar

May-2013
M T W T F S S
20 21 22 23 24 25 26
IPO
listIssue Open : Just Dial
listIssue Closing : Onesource Techm.
Economic Events
list Adjusted Merchandise Trade Balance (Yen)
list Merchandise Trade Balance Total (Yen)
Results
list Tech Mahindra